Anticorps Monoclonal anti-PPAR Gamma

PPAR Gamma Monoclonal Antibody for WB, IHC, FC (Intra), ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain, souris et plus (1)

Applications

WB, IHC, IF, FC (Intra), ChIP, ELISA

Conjugaison

Non conjugué

Publications(18)

CloneNo.

1F4A2

N° de cat : 66936-1-Ig

Synonymes

PPARG, 1F4A2, NR1C3, Peroxisome proliferator-activated receptor gamma, PPAR-gamma

---

Galerie de données de validation

• 

  WB analysis using 66936-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 66936-1-Ig (PPARG antibody) at dilution of 1:10000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 66936-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse adipose using 66936-1-Ig

  mouse adipose tissue were subjected to SDS PAGE followed by western blot with 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human prostate cancer using 66936-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 66936-1-Ig

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:1000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 66936-1-Ig

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:1000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66936-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66936-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66936-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66936-1-Ig (PPAR Gamma antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  FC experiment of HeLa using 66936-1-Ig

  1X10^6 HeLa cells were intracellularly stained with 0.4 ug Anti-Human PPAR Gamma (66936-1-Ig, Clone:1F4A2) and CoraLite®488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).

---

Applications testées

• Résultats positifs en WB: cellules HepG2, cellules A431, cellules A549, cellules HL-60, cellules K-562, cellules MCF-7, cellules PC-3, tissu adipeux de souris
• Résultats positifs en IHC: tissu de cancer de la prostate humain, tissu de cancer du côlon humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en FC (Intra): cellules HeLa,

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunohistochimie (IHC): IHC : 1:250-1:1000
• Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• WB: See 15 publications below
• IHC: See 2 publications below
• IF: See 4 publications below
• ChIP: See 1 publications below

Informations sur le produit

66936-1-Ig cible PPAR Gamma dans les applications de WB, IHC, IF, FC (Intra), ChIP, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Réactivité citée: rat, Humain, souris
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: PPAR Gamma Protéine recombinante Ag16657
• Nom complet: peroxisome proliferator-activated receptor gamma
• Masse moléculaire calculée: 58 kDa
• Poids moléculaire observé: 50 kDa
• Numéro d’acquisition GenBank: BC006811
• Symbole du gène: PPARG
• Identification du gène (NCBI): 5468
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par protéine G
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated intracellular transcription factors, members of the nuclear hormone receptor superfamily (NR), that includes estrogen, thyroid hormone receptors, retinoic acid, Vitamin D3 as well as retinoid X receptors (RXRs). The PPAR subfamily consists of three subtypes encoded by distinct genes denoted PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3), which are activated by selective ligands. PPARγ, also named as PPARG, contains one nuclear receptor DNA-binding domain and is a receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. It plays an important role in the regulation of lipid homeostasis, adipogenesis, INS resistance, and development of various organs. Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) and may be associated with susceptibility to obesity. Defects in PPARG can lead to type 2 INS-resistant diabetes and hypertension. PPARG mutations may be associated with colon cancer. Genetic variations in PPARG are associated with susceptibility to glioma type 1 (GLM1). PPARG has two isoforms with molecular weight 57 kDa and 54 kDa (PMID: 9831621), but modified PPARG is about 67 KDa (PMID: 16809887). PPARG2 is a splice variant and has an additional 30 amino acids at the N-terminus (PMID: 15689403). Experimental data indicate that a 45 kDa protein displaying three different sequences immunologically related to the nuclear receptor PPARG2 is located in mitochondria (mt-PPAR). However, the molecular weight of this protein is clearly less when compared to that of PPARG2 (57 kDa) (PMID: 10922459). PPARG has been reported to be localized mainly (but not always) in the nucleus. PPARG can also be detected in the cytoplasm and was reported to possess extra-nuclear/non-genomic actions (PMID: 17611413; 19432669; 14681322).

Publications

Species	Application	Title
human	WB	Acta Pharm Sin B; Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1.; Authors - Piao Luo
rat	WB	Phytomedicine; Podophyllotoxin via SIRT1/PPAR /NF-κB axis induced cardiac injury in rats based on the toxicological evidence chain (TEC) concept; Authors - Tao Jiang
mouse	WB	Front Immunol; miR-10a-3p modulates adiposity and suppresses adipose inflammation through TGF-β1/Smad3 signaling pathway; Authors - Sonia Kiran
mouse	WB,ChIP	Biochem Pharmacol; Flavokawain B is an effective natural peroxisome proliferator-activated receptor γ-selective agonist with a strong glucose-lowering effect; Authors - Qixin Wu
human	WB	Stem Cell Res Ther; Intranasal delivery of hMSC-derived supernatant for treatment of ischemic stroke by inhibiting the pro-inflammatory polarization of neutrophils; Authors - Yixiang Jiang
human	WB	Clin Transl Med; Oestrogen suppresses the adipogenesis of fibro/adipogenic progenitors through reactivating the METTL3-ESR1-mediated loop in post-menopausal females; Authors - Hao Zhou

{{ptg:RelatedPrimaryAntibodies}}